Navigation Links
FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
Date:9/22/2007

nsion add to a growing body of evidence about the effectiveness of Campath across the entire B-CLL treatment pathway," stated Mark Enyedy, president of Genzyme's oncology business unit. "A broader range of patients is now eligible for Campath treatment, regardless of whether they have received prior therapy. The approval also marks an important step in a long-term development plan that is exploring the full potential of Campath in high-risk CLL, combination and consolidation therapy."

Presented at the 48th Annual Meeting of the American Society of Hematology (ASH) conference last year, data supporting the sBLA were part of an international Phase III clinical trial comparing Campath with chlorambucil in previously untreated patients with B-CLL. The study met its primary endpoint by demonstrating longer progression free survival (PFS) in patients treated with Campath versus chlorambucil, with Campath reducing the risk of disease progression or death by 42 percent (p=0.0001).

Patients receiving Campath exhibited higher overall and complete response rates that were statistically significant in comparison to patients who were treated with chlorambucil. Campath also demonstrated a manageable safety profile among study patients.

"We are excited that Campath can now be used to treat patients in the U.S. earlier in the course of their disease," said Gunnar Riemann, Ph.D., member of the Board of Management of Bayer Schering Pharma AG. "The ability to now provide Campath as a first-line treatment of the disease will make an important difference in battling B-CLL. It may help patients by offering a potentially more effective treatment approach that can extend progression-free survival."

Campath is marketed in the U.S. by Bayer HealthCare Pharmaceuticals Inc., as Campath, and outside the United States as MabCampath(R).

About B-Cell Chronic Lymphocytic Leukemia

According to the Leukemia and Lymphoma Society, approximately 15,000 new cases of B-
'/>"/>

SOURCE Genzyme Corp. and Bayer HealthCare Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. FDA approves Phase 0 trial which tests experimental drugs on humans
2. FDA Approves Contraceptive Ring
3. FDA approves new device to treat womens bleeding disorder
4. FDA Approves New HIV Drug, Viread
5. FDA Approves Birth Control Skin Patch
6. FDA approves surgical gel
7. FDA Approves New Arthritis Drug, Bextra
8. FDA Approves Elidel Cream for Eczema
9. FDA approves drug for rare liver disease
10. FDA approves first pocket-sized EKG machine
11. FDA Approves New Anti-Clotting Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... nerve, from which Schwann cells, myelin sheath ... postoperative immune rejection. Simultaneously, chemically extracted acellular ... materials, such as the bottom layer of ... scaffold in the process of nerve regeneration. ... autologous nerve transplantation, can guide nerve regeneration ...
(Date:8/20/2014)... Fresh from the cradle of a world-class ... the starting blocks. , Urbini, a new collection of versatile ... Urbini Avi jogger to its lineup. , The Avi ... look inspired by the latest racing styles and a set ... versatile jogger offers a swift, smooth ride on runs, power-walks ...
(Date:8/20/2014)... August 20, 2014 The National ... five-year, $1.24 million Science Education Partnership Award (SEPA) ... support NAHN’s collaborative project with the Hispanic Communications ... Careers. , This collaborative NIH R25 program has ... and linguistic diversity among health professionals by recruiting ...
(Date:8/20/2014)... Atlantic City, New Jersey (PRWEB) August 20, 2014 ... slow in meeting the needs of an estimated tens ... the introduction of the new Bill A3525—a bill that ... eligible patients to grow their own cannabis—earlier this summer ... proper horticultural training for medicinal quality marijuana is growing. ...
(Date:8/20/2014)... 2014 Verndale is pleased to announce ... an exclusive list ranking the fastest-growing private companies in ... to their yearly percentage revenue growth over a three-year ... the Inc. 5000 list where it ranked number 2,855. ... its clients a wide range of digital marketing services ...
Breaking Medicine News(10 mins):Health News:Urbini Breezes Through Summer with New Jogging Stroller 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 3Health News:Oaksterdam University to Host Four-Day Educational Marijuana Horticultural Seminar Aug 23-26; Training Fills Information Gap for Medical Marijuana Caregivers and Patients 2Health News:Oaksterdam University to Host Four-Day Educational Marijuana Horticultural Seminar Aug 23-26; Training Fills Information Gap for Medical Marijuana Caregivers and Patients 3Health News:For the 8th Time, Verndale Has Been Honored on the Inc. 5000 List 2
... used synthetic progestin medroxyprogesterone acetate (MPA) decreased endothelial function ... University of Oregon. The finding, researchers said, raises concerns ... hormones on vascular health in young women. , The ... recent years, it has been found to be a ...
... Innovative design allows snap-on rod attachment and self-alignment ... ... Life Spine announced,today that the U.S. Food and Drug Administration ... system designed for,use in surgical lumbar fusion procedures., Life Spine,s ...
... care industry expertise has led Precyse to a leadership role, ... Operating ... WAYNE, Pa., March 10 Precyse Solutions, the leader ... the appointment of Ken Lacy as Senior Vice,President and Chief ...
... March 10 NBTY, Inc. (NYSE:,NTY) (http://www.NBTY.com ), ... announced that it will web cast the,presentation by Harvey ... Bank of America Consumer Conference in New York on ... be web cast live on the Company Web,site, ...
... precise control of ... key to averting brain damage, LOUISVILLE, Colo., March 10 ... most effective cooling technology-the,non- invasive Arctic Sun(R)-is increasing rapidly. The ... ill,patients with the Arctic Sun rose to more than 72 ...
... abnormal Pap test results happened after girls and women were ... researcher at the University of Alabama at Birmingham (UAB). , ... the development of cell changes that lead to cervical disease, ... test results by 43 percent compared to women not given ...
Cached Medicine News:Health News:Oregon study raises questions on synthetic progestins 2Health News:Oregon study raises questions on synthetic progestins 3Health News:Life Spine Adds New Lynx(TM) Cross Connector to Its Lumbar Fixation Offering 2Health News:Precyse Solutions Promotes Ken Lacy to Senior Vice President & CIO to Drive Advancement of PrecyseNet(TM), Precyse's Advanced Technology Solution 2Health News:NBTY to Webcast Presentation at Bank of America Consumer Conference: Announces Preliminary Sales and the Repurchase of 6.1 Million Shares 2Health News:NBTY to Webcast Presentation at Bank of America Consumer Conference: Announces Preliminary Sales and the Repurchase of 6.1 Million Shares 3Health News:More than Seventy Percent of Top US Hospitals Control Patient Temperature with High-Tech Arctic Sun(TM) 2Health News:HPV vaccine reduces abnormal pap test results 2
(Date:8/20/2014)... , Aug. 20, 2014   Easy Breathe , the fastest ... its " Easy Blog " - has received more than 4.5 ... "We are thrilled that so many people are finding ... CEO of Easy Breathe. "We,re committed to making sleep apnea more ... to stay informed about sleep apnea news , troubleshooting ...
(Date:8/20/2014)... Texas , Aug. 20, 2014  Quantum ... five diverse sets of patent families from Bayer Technology ... innovation driver for Bayer AG of Leverkusen, ... patents acquired provide broad intellectual property protection for ... economical high-volume quantum dot (QD) manufacturing. In addition, ...
(Date:8/19/2014)... 19, 2014  The Alabama Supreme Court, in a 6-3 ... drug makers who mislead doctors into believing that prescription medicines ... is Weeks v. Wyeth, and the decision came after the ... case last year. Heninger Garrison Davis attorneys Lew Garrison ... the case, Danny Weeks . The decision ...
Breaking Medicine Technology:Easy Breathe Blog Emerges as the Go-To Resource for Sleep Apnea Sufferers 2Easy Breathe Blog Emerges as the Go-To Resource for Sleep Apnea Sufferers 3Easy Breathe Blog Emerges as the Go-To Resource for Sleep Apnea Sufferers 4Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 2Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 3Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 4Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 2Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 4
... CMIS Telemetry System is a telemetry ... hospitals which require monitoring and performance. ... are able to monitor patients from ... transmitters and wireless bedsides. Now, monitoring ...
... Telemetry System, portable TeleMon companion monitor, ... integrated surveillance and monitoring solution for ... of ECG and SpO2. Clinicians can ... patient information from the central station, ...
TeleRehab Advantage is a monitoring system that automates the generation of outcomes data. Patient information and session information is automatically transferred from the monitoring program to Outc...
ISI DuraHand is the reusable, easy to sterilize surgical hand immobilizer....
Medicine Products: